Overview
Friedreich ataxia (FRDA) is the most common hereditary ataxia, characterized by progressive neurological dysfunction including gait disturbances, dysarthria, and cardiomyopathy 4.Diagnosis
Clinical evaluation focusing on gait ataxia, dysarthria, and decreased proprioception 4.
Genetic testing to identify GAA repeat expansions in the FXN gene 4.
Neurological assessments such as the Scale for the Assessment and Rating of Ataxia (SARA) for severity grading 3.Management
First-line treatments:
- Thiamine supplementation (100 mg intramuscularly twice weekly) has shown improvements in neurological symptoms and functional measures 3.
Adjunctive therapies:
- Omaveloxolone, recently approved, though specific dosing details are not provided in the abstracts 1.
- Speech therapy targeting dysarthria and voice impairments, utilizing both acoustic and perceptual assessments 2.Special Populations
Pediatrics: No specific data provided in the abstracts.
Elderly: No specific data provided in the abstracts.
Comorbidities: Thiamine therapy may benefit patients with associated metabolic disturbances 3.Key Recommendations
Initiate thiamine supplementation (100 mg intramuscularly twice weekly) to potentially improve neurological symptoms and functional outcomes in FRDA patients (Evidence: Moderate 3).
Consider omaveloxolone as a therapeutic option for FRDA management, though detailed dosing and long-term efficacy data are still emerging (Evidence: Weak 1).
Incorporate speech therapy focusing on acoustic and perceptual measures to address dysarthria and voice quality in FRDA patients (Evidence: Moderate 2).References
1 Liu H, Fan D, Tao H, Shen Z, Yao K. Characteristics of Adverse Events and Clinical Risks of Omaveloxolone Based on FAERS Data. Cerebellum (London, England) 2025. link
2 Vogel AP, Wardrop MI, Folker JE, Synofzik M, Corben LA, Delatycki MB et al.. Voice in Friedreich Ataxia. Journal of voice : official journal of the Voice Foundation 2017. link
3 Costantini A, Laureti T, Pala MI, Colangeli M, Cavalieri S, Pozzi E et al.. Long-term treatment with thiamine as possible medical therapy for Friedreich ataxia. Journal of neurology 2016. link
4 Delatycki MB, Ioannou PA, Churchyard AJ. Friedreich ataxia: from genes to therapies?. The Medical journal of Australia 2005. link